Application
Hydroxyflutamide has been used:
- as an androgen receptor antagonist to study its effects on cardiomyocyte hypertrophy induced by dihydrtestosterone (DHT) in primary neonatal rat ventricular cardiomyocyte and rat cardio myoblast (H9c2) cells.
- as an androgen receptor antagonist for the treatment of MDA-kb2 cells to check its effect on luciferase expression.
- as an antagonist control in transcriptional activation assay.
Biochem/physiol Actions
Hydroxflutamide is an AR antagonist. Androgen receptors (ARs) are nuclear hormone receptors/transcription factors. Hydroxyflutamide is an androgen antagonist with publications going back to 1981. It is one of a few gold standard AR antagonists; activities of new antagonists are measured against hydroxyflutamide.
Hydroxyflutamide plays a role in preventing the binding of 5α-dihydrotestosterone (DHT) and testosterone to the androgen receptors.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
- UPC:
- 51111606
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- H4166-25MG
